Related Experiment Videos
The great debate at "Melanoma Bridge 2018", Naples, December 1st, 2018
Paolo A Ascierto1, Paolo Bruzzi2, Alexander Eggermont3
1Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Via Mariano Semmola, 80131, Naples, Italy. paolo.ascierto@gmail.com.
Abstract:
The great debate session at the 2018 Melanoma Bridge congress (November 29-December 1, Naples, Italy) featured counterpoint views from experts on three topical issues in melanoma. These were whether overall survival should still be the main endpoint for clinical trials in melanoma, whether anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 is still the optimal choice of drug to use in combination with an anti-programmed death (PD)/PD-ligand (L)-1 agent, and the place of adjuvant versus neoadjuvant therapy in patients with melanoma. These three important debates are summarised in this report.
Insights
Experts debated key melanoma treatment strategies in 2018. Discussions focused on clinical trial endpoints, combination immunotherapy options like anti-CTLA-4 with anti-PD-1/PD-L1, and neoadjuvant versus adjuvant therapy.
Area of Science:
- Oncology
- Immunology
- Clinical Trials
Background:
- Melanoma treatment landscape is rapidly evolving.
- Key questions remain regarding optimal clinical trial design and therapeutic strategies.